Literature DB >> 14735579

Prader-Willi syndrome: causes of death in an international series of 27 cases.

Constance Th R M Schrander-Stumpel1, Leopold M G Curfs, Prapto Sastrowijoto, Suzanne B Cassidy, Jaap J P Schrander, Jean-Pierre Fryns.   

Abstract

Prader-Willi syndrome (PWS) is a complex condition with many medical and psychological features. In individuals with this syndrome, causes of death were studied. Data of 27 case reports were collected. Ages at death ranged from neonatal to 68 years. None of the individuals were treated with growth hormone (GH). Most cases were not completely documented and autopsy was performed in a minority of cases only. In five cases, death was considered not to be causally related to PWS. Hypotonia with hypoventilation was noted in the babies, and acute respiratory illness with unexpected sudden death was experienced in young children with PWS. Two young children died after a short period of fever and gastroenteritis. Obesity and its complications leading to death were pronounced in the adult group. One (possibly two) adult(s) died from gastric dilatation and shock. Based on these data, some cautious conclusions can be drawn. In babies with PWS hypoventilation is a risk factor; upper airway infection may be more serious than anticipated and any other clinical features pointing to an infection should be taken very seriously. Therefore, young infants with PWS hospitalized with an upper airway infection and/or hypoventilation or gastroenteritis symptoms, should be closely monitored. Early diagnosis and prevention of overweight is a major factor in preventing early causes of death in individuals with PWS. In the adult group, weight reduction is important but difficult to manage. Sleep apnea should be recognized and treated. Pain in the upper stomach and/or vomiting should be taken as a possible sign of acute intestinal dilatation; intravenous support may be life saving. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14735579     DOI: 10.1002/ajmg.a.20371

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  42 in total

Review 1.  Death during GH therapy in children with Prader-Willi syndrome: description of two new cases.

Authors:  G Grugni; C Livieri; A Corrias; A Sartorio; A Crinò
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

2.  Long-term health outcomes in patients with Prader-Willi Syndrome: a nationwide cohort study in Denmark.

Authors:  E Hedgeman; S P Ulrichsen; S Carter; N C Kreher; K P Malobisky; M M Braun; J Fryzek; M S Olsen
Journal:  Int J Obes (Lond)       Date:  2017-06-21       Impact factor: 5.095

3.  Relations among functional systems in behavior analysis.

Authors:  Travis Thompson
Journal:  J Exp Anal Behav       Date:  2007-05       Impact factor: 2.468

4.  Human growth hormone therapy in Prader-Willi syndrome.

Authors: 
Journal:  Paediatr Child Health       Date:  2005-04       Impact factor: 2.253

Review 5.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

6.  Contributing factors of mortality in Prader-Willi syndrome.

Authors:  Jennifer Proffitt; Kathryn Osann; Barbara McManus; Virginia E Kimonis; Janalee Heinemann; Merlin G Butler; David A Stevenson; June-Anne Gold
Journal:  Am J Med Genet A       Date:  2018-12-19       Impact factor: 2.802

7.  Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatment.

Authors:  T Cadoudal; M Buléon; C Sengenès; G Diene; F Desneulin; C Molinas; S Eddiry; F Conte-Auriol; D Daviaud; P G P Martin; A Bouloumié; J-P Salles; M Tauber; P Valet
Journal:  Int J Obes (Lond)       Date:  2014-01-10       Impact factor: 5.095

8.  Sudden cardiac death in a child affected by Prader-Willi syndrome.

Authors:  Cristoforo Pomara; Stefano D'Errico; Irene Riezzo; Gian Pio de Cillis; Vittorio Fineschi
Journal:  Int J Legal Med       Date:  2005-03-05       Impact factor: 2.686

9.  Growth hormone therapy improves exercise capacity in adult patients with Prader-Willi syndrome.

Authors:  L A Gondoni; L Vismara; P Marzullo; R Vettor; A Liuzzi; G Grugni
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

10.  Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study.

Authors:  Jennifer L Miller; Jonathan Shuster; Douglas Theriaque; Daniel J Driscoll; Mary Wagner
Journal:  J Clin Sleep Med       Date:  2009-10-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.